Completed PHASE2 INTERVENTIONAL 7-arm NCT01704404

7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

A Phase 2 Study of the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD-4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease

Sponsor: Mylan Inc.

Conditions COPD

Interventions Placebo TD-4208

Updated 11 times since 2017 Last updated: Feb 22, 2022 Started: Dec 31, 2012 Primary completion: Nov 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01704404, this PHASE2 trial focuses on COPD and remains completed. Sponsored by Mylan Inc., it has been updated 11 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2
Jun 2021 — Mar 2022 [monthly]

Completed PHASE2
Jan 2021 — Jun 2021 [monthly]

Completed PHASE2

▶ Show 6 earlier versions

Sep 2020 — Jan 2021 [monthly]

Completed PHASE2
Dec 2019 — Sep 2020 [monthly]

Completed PHASE2
Oct 2018 — Dec 2019 [monthly]

Completed PHASE2
Jun 2018 — Oct 2018 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — May 2017 [monthly]

Completed PHASE2

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mylan Inc.
Theravance Biopharma

Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wellington, New Zealand